CDKN2A and lung carcinoma: Analysis indicated that CDKN2A, FAT1, MSH6, ARID1A, KEAP1, NF1, and SMAD4 mutation was more recurrent in patients with ERBB2 SNV/indels within the kinase domain compared with non-kinase domain in lung cancer (Figure 2E).